All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-01-08T12:29:40.000Z

Highlights for MRD assessment in AML

By Paola Frisone
Featured
Lars Bullinger
Jan 8, 2021
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, about the highlights for measurable residual disease (MRD) assessment in AML from ASH 2020.

ASH 2020: Highlights for MRD assessment in AML

Bullinger mentions three studies presented at ASH 2020: the first one investigating the effectiveness of MRD eradication with chemotherapy prior to allogeneic stem cell transplantation in AML; the second study evaluating NPM1 as a molecular marker for MRD; and the last one focusing on new technologies for MRD assessment.

Bullinger kindly gave his interview in German, with the title 'ASH 2020: Highlights zum MRD Monitoring bei der AML'.

 

More about...
AML-related mutationsASH 2020De novoDiseaseNPM1SecondaryTherapy-related

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

What has ASH 2020 taught us about advancing frontline chemotherapy in AML?

Increased understanding of the driving genetic and epigenetic factors of acute myeloid leukemia (AML) in recent years has helped to refine novel chemotherapy combinations in...

Feb 12, 2021
Add bookmark

What has ASH 2020 taught us about advancing frontline chemotherapy in AML?

Increased understanding of the driving genetic and epigenetic factors of acute myeloid leukemia (AML) in recent years has...

Feb 12, 2021
Add bookmark

ASH 2018 | Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia – CAVEAT study

Venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable and is associated with a high CR/CRi in patients...

Dec 12, 2018
Add bookmark

ASH 2018 | Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia – CAVEAT study

Venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable...

Dec 12, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox